Preclinical and clinical data demonstrated efficacy in inflammatory, neuropathic, and cancer-associated pain, with lower risks of respiratory depression, tolerance, dependence, and abuse compared to MOR agonists. This evidence concerns the gene OPRM1 and cancer.